



## Serum CrossLaps<sup>®</sup> (CTX-I) ELISA

The Serum CrossLaps<sup>®</sup> (CTX-I) ELISA is an enzyme immunological test for the quantification of degradation products of C-terminal telopeptides of Type I collagen in human serum and plasma. It is intended for *in vitro* diagnostic use as an indication of human bone resorption, and may be used as an aid in monitoring bone resorption changes following anti-resorptive therapies in postmenopausal women and individuals diagnosed with osteopenia. It may also be used for predicting skeletal response (bone mineral density) in postmenopausal women undergoing anti resorptive therapies.

Type I collagen accounts for more than 90% of the organic matrix of bone and is synthesised primarily in bone<sup>1</sup>. During renewal of the skeleton, Type I collagen is degraded, and small peptide fragments are excreted into the bloodstream which can be measured by the Serum CrossLaps<sup>®</sup> (CTX-I) ELISA. The measurements of the specific degradation products of Type I collagen in both urine<sup>2</sup> and serum<sup>3</sup> by a competitive CrossLaps assay have been reported.

The sandwich assay has been reported as useful for follow up of anti-resorptive treatment of patients with metabolic bone diseases<sup>3-8</sup>.

### Features and benefits

- Suitable for measurement of a variety of sample types.
- Highly correlated with an established automated assay.
- Excellent sensitivity and reproducible results – providing a useful tool in therapy monitoring.
- Supported by a comprehensive portfolio of both bone formation and resorption markers.

# Specifications

Format	Manual monoclonal antibody enzyme-linked immunosorbent assay			
Calibrators	Ready to use – 1 each of 6 concentration levels, 1 x 5.0 mL of calibrator 0 and 1 x 0.4 mL of calibrators 1 – 5			
Controls	Ready to use – 1 x 0.4 mL 2 concentration levels			
Minimum detectable	0.020 ng/mL			
Reference Range	Population	n	Mean (ng/mL)	95% Confidence Interval (ng/mL)
	Males	125	0.294	0.115 – 0.748
	Pre-menopausal females	226	0.287	0.112 – 0.738
	Post-menopausal females	193	0.439	0.142 – 1.351
Sample volume	50 µL			
Sample type	Human serum and heparin / EDTA plasma			
Reagent stability	The Serum CrossLaps® (CTX-I) ELSIA assay reagents are to be stored at 2-8°C. At this temperature they are stable until the expiration date printed on the box label			
Precision	Sample ID	Mean (µg/L)	Within Run	Between Run
	1	0.121	3.0%	10.9%
	2	0.444	1.7%	9.7%
	3	1.967	1.8%	2.5%


## Ordering information

Product Name	Size	Code
Serum CrossLaps® (CTX-I) ELISA	96 wells	AC-02F1

## Method comparison

## Complementary products

Product Name	Size	Code
Alpha CrossLaps® (CTX-I) ELISA	96 wells	AC-04F1
BoneTRAP® (TRAcP 5b) ELISA	96 wells	SB-TR201A
N-MID® Osteocalcin ELISA	96 wells	AC-11F1
Ostase® BAP EIA	96 wells	AC-20F1
Urine BETA CrossLaps® (CTX-I) ELISA	96 wells	AC-05F1
Urine CrossLaps® (CTX-I) EIA	96 wells	AC-03F1



Visit [www.idsplc.com](http://www.idsplc.com) for an extended range of IDS assays

### References

- Bjarnason NH, & Christiansen, C. Early Response in Biochemical Markers Predicts Long-term Response in Bone Mass During Hormone Replacement Therapy in Early Postmenopausal Women. Elsevier 26; 561-569 (2000).
- Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of Type I collagen. J Bone Miner Res 12:1028-1034 (1997).
- Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps®) - follow up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol & Metab 80:864-8 (1995).
- Buclin T, Rochat MC, Burckhardt P, Azria M, Attinger M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 17;8-1478 (2002).
- Burgeson RE. New collagens, new concepts. Annu Rev Cell Biol 4:551-77 (1988).
- Chailurkit LO, Aunphongpuwanart S, Ongphiphadhanakul B, Jongjaroenprasert W, Sae-Tung S, and Rajatanavin R. Efficacy of intermittent low dose alendronate in Thai postmenopausal osteoporosis. Endocr Res 30:29-36 (2004).
- Christgau S, Bitsch-Jensen O, Bjarnason NH, Gamwell Henriksen E, Qvist P, Alexandersen P, Bang Henriksen D. Serum CrossLaps for Monitoring the Response in Individuals Undergoing Antiresorptive Therapy. Elsevier 26; 505-511 (2000).
- Christgau S, Rosenquist C, Alexandersen P, Bjarnason NH, Ravn P, Fledelius C, Herling C, Qvist P, Christiansen C. Clinical evaluation of the Serum CrossLaps® ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44:11:2290-2300 (1998).